Thank you bigJake...so Madigal has less than 3X as much money (300+ to 100+M, both heavily cashed up to put it mildly, an otherwise great sign) and a market cap of 6.5X that of VKTX, but VkTX has a more effective compound. (putting aside VKTX's very promising ortho compound for a moment). Either they are wildly overvalued or Viking wildly undervalued. One can argue the valuations should be reversed. There is no argument that our compound is unsafe, and it is more effective than theirs. Effectiveness trumps everything else by far, but the market is massive so there is room for both, and several others to be sure.
This medical market is in the double digit Billions, per year....massive. U.S. only that is.
My conclusion is that this is a market, as in the company's now competing in it, that is just getting started. Like several years ago the immuno cancer stocks started very small in terms of their market caps and within two years exploded higher and higher...etc
I read the market demand for these compounds was estimated at 10 to 20 Billion.
My conclusion is this market is just getting started, so too the stocks in it. Even a billion dollar drug per year is a mammoth blockbuster, justifying a cap much larger than Madigal's current cap, which, FOR NOW, drawfs Viking's cap.....Again, I think these stocks are just getting out of the gate, just starting their run. Especially given the apparent effectivness.
A cancer drug that shows this sort of effectiveness would be many times Viking's current cap. Even now.
News 
Market Data 
Discover 
